{"id":"W4384938676","doi":"10.1016/j.ejca.2023.113245","title":"Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; U.S. Food and Drug Administration; Ipsen; PharmaMar; Eisai; MacroGenics; Pfizer; Symphogen; Incyte; Amgen; Deciphera Pharmaceuticals; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Exelixis; Karyopharm Therapeutics; Iterion Therapeutics; Sanofi; PTC Therapeutics; GlaxoSmithKline; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; AstraZeneca; Springworks Therapeutics; Abbott Laboratories","keywords":"Tolerability; Sunitinib; Medicine; Imatinib; Open label; Oncology; Internal medicine; Adverse effect; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001980855,0.0006087039,0.002102068,0.0002284816,0.0003142638,0.0007600366,0.0003503071,0.0007989472,0.00192069],"category_scores_gemma":[0.001527207,0.0002228879,0.002531554,0.0003059772,0.0004390437,0.001001955,0.0002566115,0.001859984,0.0003145993],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004881358,"about_ca_system_score_gemma":0.0004013509,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002585553,"about_ca_topic_score_gemma":0.0006996101,"domain_scores_codex":[0.9993393,0.0003044554,0.00005616733,0.0001171566,0.00008232233,0.0001006403],"domain_scores_gemma":[0.9987227,0.0003853677,0.0004726388,0.00007083948,0.00005961848,0.0002887101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8567035,0.009287852,0.05039217,0.001060424,0.006172121,0.0002250727,0.0002210446,0.002110193,0.01072316,0.0001557967,0.001519467,0.06142927],"study_design_scores_gemma":[0.2529784,0.4430531,0.2818774,0.0001403718,0.008274532,0.0008397151,0.0002905788,0.004221368,0.004133404,0.0005883464,0.003420871,0.0001819383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962659,0.002284288,0.0001272048,0.000103103,0.0000407505,0.0001249247,0.0004895099,0.00001530033,0.0005489326],"genre_scores_gemma":[0.9974945,0.00055599,0.0002050911,0.0002219766,0.00007262915,0.0002025996,0.0007969846,0.00000633631,0.000443875],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002102068,"threshold_uncertainty_score":0.01047587,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07365699301019253,"score_gpt":0.3952851022484515,"score_spread":0.321628109238259,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}